Media Release Osteoporosis Canada and the International Osteoporosis Foundation underline their shared goal of improving clinical outcomes and preventing recurrent fractures in patients who have sustained fractures due to osteoporosis. […]

Prepared and reviewed by members of the Scientific Advisory Council of Osteoporosis Canada • Dr. Rick Adachi, Rheumatologist, McMaster University • Dr. Robert Josse, Endocrinologist, University of Toronto • Dr. […]

Advocate Educate, empower and support In keeping with our mission to educate, empower and support individuals and communities in the prevention and treatment of osteoporosis, Osteoporosis Canada communicates concerns about various […]

Introducing a fashion line inspired by the two million Canadians affected by osteoporosis TORONTO, Feb. 6, 2019  – Models clad in stylish bubble wrap strutted down the Toronto Fashion Week® x […]

We are aware of recent media reports that long-term use of bisphosphonates for osteoporosis (sold under the names of Fosamax [alendronate] and Actonel [risedronate]) may be associated with the occurrence […]

DONATE Your Donations Go a Long Way We were the world’s first-ever osteoporosis-dedicated organization, the first to establish guidelines for long-term treatment and exercise, and the first to introduce fracture […]

We are aware of recent media reports that long-term use of bisphosphonates for osteoporosis (sold under the names of Fosamax [alendronate] and Actonel [risedronate]) may be associated with the occurrence […]

BISPHOSPHONATES The most common family of drugs used to treat osteoporosis Bisphosphonates are the most common family of drugs used to treat osteoporosis. They are part of the group of […]

Osteoporosis Canada continues to advise Canadians to meet the Institute of Medicine established daily calcium requirement of 1000 -1200 mg, from dietary sources preferably, and to use supplements if this […]